June 18, 2021Open Access

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

JFJohn FraterUniversity of Oxford KEKatie EwerUniversity of Oxford AOAne OgbeUniversity of Oxford

Key Points

Key points are not available for this paper at this time.

Abstract

UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca.

AI에게 질문

Bookmark

View Full Paper